Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats

Table 1 Macroscopic results

Group	I (n = 14)	II (n = 15)	III (n = 11)	IV (n = 6)	V (n = 5)	VI (n = 6)
Inflammation	14	15	11	6	5	6
Ulcerated mucosa,%	35.7	37.3	33.18	39.58	16	14.17
Squamous hyperplasia,%	10	14	2	5	2	2
Intestinal metaplasia in continuity with anastomosis, mm	2.29	3.5	2.32	2.83	2	1.25
Intestinal metaplasia beyond anastomosis,%	10	9	5	4	1	0
Dysplasia	14	14	10	6	5	5
High-grade dysplasia/low-to-medium grade dysplasia	10/4	12/2	4/6	4/2	0/5	1/4
Neoplasia	8	9	4	3	-	-
Mucinous adenocarcinoma	7	9	3	2	-	-
Squamous adenocarcinoma	1	-	1	1	-	-

Table 2 Esophageal prostaglandin E2 levels in rats at 2 mo and 4 mo (mean ± SE, ng/g)

	2 mo	4 mo
Without treatment	1332.7 ± 656.7	1121.6 ± 1015.6
MF-tricyclic	1776.8 ± 1403.3	1914.9 ± 1905.5
Indomethacin	480.3 ± 333.4	243.9 ± 85.7

MF-tricyclic: 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.